pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.
Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.
Correale
M
M
RIA Laboratory, Oncology Institute of Bari, Italy.
Abbate
I
I
Paradiso
A
A
Schittulli
F
F
Dragone
C D
CD
Tedone
T
T
Gargano
G
G
Catino
A M
AM
Musci
M D
MD
De Lena
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D015415:Biomarkers / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000503:physiopathology; D002277:Carcinoma / Q000175:diagnosis* / Q000503:physiopathology; D003600:Cytosol / Q000737:chemistry; D004967:Estrogens / Q000502:physiology; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D008875:Middle Aged; D018777:Multiple Chemical Sensitivity; D009363:Neoplasm Proteins / Q000097:blood / Q000276:immunology; D011379:Prognosis; D011506:Proteins; D011960:Receptors, Estrogen / Q000502:physiology; D011980:Receptors, Progesterone / Q000502:physiology; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D004967:Estrogens; D009363:Neoplasm Proteins; D011506:Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins